Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Nanobiotix S.A.

< Previous 1 2 Next >
NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX to Participate in Multiple Investor Conferences in November
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX to Present at the Jefferies Global Healthcare Conference
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS